Literature DB >> 26223336

Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality.

Sumul Modi1, Devanshi Dharaiya2, Lonni Schultz3, Panayiotis Varelas4.   

Abstract

OBJECTIVE: Our study objective was to identify real-world rates of complications, mortality, and outcomes in patients with neuroleptic malignant syndrome (NMS) over the last decade in the United States.
METHODS: A total of 1346 patients were obtained from the nationwide inpatient sample for the years 2002-2011. Common complications known to be associated with NMS were identified. Multivariable regression analyses were used to identify predictors of mortality.
RESULTS: The most prevalent complication was rhabdomyolysis (30.1%). Other common complications were acute respiratory failure (16.1%), acute kidney injury (17.7%), sepsis (6.2%), and other systemic infections. Unadjusted mortality rate was 5.6%. Older age, acute respiratory failure, acute kidney injury, sepsis, and comorbid congestive heart failure were significant predictors of mortality. Acute respiratory failure was the strongest independent mortality predictor (p < 0.001).
CONCLUSION: In our large sample population-based study on NMS, we were able to identify the rates of several preselected complications and the mortality. The identification of independent mortality predictors in this study can guide physicians in the management and prognostication of this rare syndrome.

Entities:  

Keywords:  Complications; Mortality; Neuroleptic malignant syndrome; Outcome

Mesh:

Year:  2016        PMID: 26223336     DOI: 10.1007/s12028-015-0162-5

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  18 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Nontraumatic rhabdomyolysis and acute renal failure.

Authors:  R A Grossman; R W Hamilton; B M Morse; A S Penn; M Goldberg
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

3.  Neuroleptic malignant syndrome: review and analysis of 115 cases.

Authors:  G Addonizio; V L Susman; S D Roth
Journal:  Biol Psychiatry       Date:  1987-08       Impact factor: 13.382

Review 4.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

Review 5.  Mortality from neuroleptic malignant syndrome.

Authors:  A Shalev; H Hermesh; H Munitz
Journal:  J Clin Psychiatry       Date:  1989-01       Impact factor: 4.384

Review 6.  The neuroleptic malignant syndrome--a review.

Authors:  W R Gibb; A J Lees
Journal:  Q J Med       Date:  1985-08

Review 7.  The neuroleptic malignant syndrome: a review.

Authors:  A Lazarus
Journal:  Can J Psychiatry       Date:  1986-10       Impact factor: 4.356

Review 8.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Successful treatment of six patients with neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure.

Authors:  Toru Sanai; Rei Matsui; Tadashi Hirano; Shinichi Torichigai; Hideki Yotsueda; Harumichi Higashi; Hideki Hirakata; Mitsuo Iida
Journal:  Ren Fail       Date:  2006       Impact factor: 2.606

Review 10.  The neuroleptic malignant syndrome: agent and host interaction.

Authors:  A Shalev; H Munitz
Journal:  Acta Psychiatr Scand       Date:  1986-04       Impact factor: 6.392

View more
  15 in total

Review 1.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

2.  Neuroleptic malignant syndrome as part of an akinetic crisis associated with sepsis in a patient with Lewy body disease.

Authors:  Saki Manabe; Hidetaka Yanagi; Hideki Ozawa; Atsushi Takagi
Journal:  BMJ Case Rep       Date:  2019-02-28

3.  Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge.

Authors:  David Choon Liang Teo; Hon Khuan Wong; Sheng Neng Tan
Journal:  Innov Clin Neurosci       Date:  2018-08-01

4.  Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association.

Authors:  Siddharth Sarkar; Nitin Gupta
Journal:  BJPsych Bull       Date:  2017-08

5.  Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription.

Authors:  Thomas J Reilly; Sean Cross; David M Taylor; Richard Haslam; Sophie C Tomlin; Benjamin Gaastra
Journal:  SAGE Open Med Case Rep       Date:  2017-03-31

Review 6.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

7.  Acute Abdomen with Ileus: A Heralding Presentation of Neuroleptic Malignant Syndrome.

Authors:  Chukwunonso Chime; Ahmed Alemam; Kishore Kumar; Manjeet Dhallu
Journal:  Case Rep Gastroenterol       Date:  2018-09-18

8.  Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

Authors:  Shaina Musco; Laura Ruekert; Jaclyn Myers; Dennis Anderson; Michael Welling; Elizabeth Ann Cunningham
Journal:  J Clin Psychopharmacol       Date:  2019 Jul/Aug       Impact factor: 3.153

9.  The Role of Physical Examinations in Psychiatry as Illustrated in a Case of Neuroleptic Malignant Syndrome Versus Viral Encephalitis: A Case Report and Literature Review.

Authors:  Michael Esang; Sabina Goldstein; Ravina Dhami
Journal:  Cureus       Date:  2019-06-05

10.  Diagnosis and implications in the therapeutic management of patient with afebrile neurolepctic malignant syndrome.

Authors:  Rafael Quintes Ducasble Gomes; Amilton Dos Santos-Júnior; Gabriel Augusto de Araujo Silva Dias; Carlos Filinto da Silva Cais
Journal:  Oxf Med Case Reports       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.